146 related articles for article (PubMed ID: 23233241)
1. Fidaxomicin in the treatment of Clostridium difficile-associated diarrhoea.
Greig J
Clin Drug Investig; 2013 Jan; 33(1):93-4. PubMed ID: 23233241
[No Abstract] [Full Text] [Related]
2. Fidaxomicin in the treatment of Clostridium difficile-associated diarrhoea.
Sclar DA; Robison LM; Oganov AM; Schmidt JM; Bowan KA; Castillo LV
Clin Drug Investig; 2013 Mar; 33(3):229. PubMed ID: 23386229
[No Abstract] [Full Text] [Related]
3. An economic analysis: is fidaxomicin worth the cost?
Shah H; Doyle JJ; Belletti DA
Clin Infect Dis; 2014 Feb; 58(4):603-4. PubMed ID: 24300041
[No Abstract] [Full Text] [Related]
4. Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price.
Sclar DA; Robison LM; Oganov AM; Schmidt JM; Bowen KA; Castillo LV
Clin Drug Investig; 2012 Aug; 32(8):e17-24. PubMed ID: 22708825
[TBL] [Abstract][Full Text] [Related]
5. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
Petrella LA; Sambol SP; Cheknis A; Nagaro K; Kean Y; Sears PS; Babakhani F; Johnson S; Gerding DN
Clin Infect Dis; 2012 Aug; 55(3):351-7. PubMed ID: 22523271
[TBL] [Abstract][Full Text] [Related]
6. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.
Weiss K; Allgren RL; Sellers S
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S110-5. PubMed ID: 22752858
[TBL] [Abstract][Full Text] [Related]
7. Is fidaxomicin worth the cost? An economic analysis.
Bartsch SM; Umscheid CA; Fishman N; Lee BY
Clin Infect Dis; 2013 Aug; 57(4):555-61. PubMed ID: 23704121
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and Treatment of Clostridioides (Clostridium) difficile Infection in Adults in 2020.
Rao K; Malani PN
JAMA; 2020 Apr; 323(14):1403-1404. PubMed ID: 32150234
[No Abstract] [Full Text] [Related]
9. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.
Figueroa I; Johnson S; Sambol SP; Goldstein EJ; Citron DM; Gerding DN
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S104-9. PubMed ID: 22752857
[TBL] [Abstract][Full Text] [Related]
10. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
[TBL] [Abstract][Full Text] [Related]
11. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
12. Treating Clostridium difficile infection.
Shafran DM; Shafran SD
CMAJ; 2014 Apr; 186(7):531. PubMed ID: 24344151
[No Abstract] [Full Text] [Related]
13. Fidaxomicin, a new treatment for Clostridium difficile infections.
Epstein L; Golan Y
Drugs Today (Barc); 2012 Feb; 48(2):101-8. PubMed ID: 22384450
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies.
Chen LF; Anderson DJ
Future Microbiol; 2012 Jun; 7(6):677-83. PubMed ID: 22702523
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
[TBL] [Abstract][Full Text] [Related]
16. A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences.
Skinner AM; Tan X; Sirbu BD; Danziger LH; Gerding DN; Johnson S
Clin Infect Dis; 2021 Sep; 73(6):1107-1109. PubMed ID: 33714998
[TBL] [Abstract][Full Text] [Related]
17. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.
Tannock GW; Munro K; Taylor C; Lawley B; Young W; Byrne B; Emery J; Louie T
Microbiology (Reading); 2010 Nov; 156(Pt 11):3354-3359. PubMed ID: 20724385
[TBL] [Abstract][Full Text] [Related]
18. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
[TBL] [Abstract][Full Text] [Related]
19. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
Crook DW; Walker AS; Kean Y; Weiss K; Cornely OA; Miller MA; Esposito R; Louie TJ; Stoesser NE; Young BC; Angus BJ; Gorbach SL; Peto TE;
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S93-103. PubMed ID: 22752871
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]